We report here the production and the properties of single chain Fv fragments (scFvs) derived from the antip53 monoclonal antibodies PAb421 and 11D3. 11D3 is a newly generated monoclonal antibody which exhibits properties very comparable to those of PAb421. The scFvs PAb421 and 11D3 are able to stably associate with p53 and to restore the DNA binding activity of some p53 mutants in vitro. When expressed in p53 7/7 human tumour cells, the scFv421 is essentially localized in the cytoplasm in the absence of p53, and in the nucleus when exogenous p53 is present. Thus, p53 is also able to stably associate with an anti-p53 scFv in cells. Cotransfection of p53 7/7 human tumour cells with expression vectors encoding the His273 p53 mutant and either scFv leads to restoration of the p53 mutant de®cient transcriptional activity. These data demonstrate that, in human tumour cells, these scFvs are able to restore a function essential for the tumour suppressor activity of p53 and may represent a novel class of molecules for p53-based cancer therapy.
Keywords: p53; scFv; intracellular immunization; gene therapy Mutations in the p53 tumour suppressor gene are a very common event in human tumours (Hainaut et al., 1997) . Wild-type (wt) p53 acts as a tumour suppressor gene product (Finlay et al., 1989) , inhibiting the proliferation of tumour cells in culture and suppressing the tumourigenicity of tumour cells in nude mice (Baker et al., 1990; Mercer et al., 1990) . It is clearly involved in the cell cycle arrest resulting of a genomic stress (UV irradiation or chemotherapeutic agent), in DNA repair and apoptosis (Kastan et al., 1991; Clarke et al., 1993; Lowe et al., 1993; Lu and Lane, 1993; Zhan et al., 1993; Eizenberg et al., 1995; Guillouf et al., 1995; Lee et al., 1995; Smith et al., 1995) . Wt p53 is a sequence-speci®c transcription factor, which regulates the expression of genes involved in growth control and apoptosis, such as p21/WAF1/CIP1 (E1-Deiry et al., 1993), GADD45 (Kastan et al., 1992) , IGF-BP3 (Buckbinder et al., 1995) , Bax (Miyashita et al., 1995) , FAS/APO1 (OwenShaub et al., 1995) and more recently, genes involved in free radical formation (Polyak et al., 1997; see Ko and Prives, 1996; Levine, 1997, for review) .
In many human tumours, a missense mutation is found essentially in the exons of the p53 gene which encode the sequence-speci®c DNA binding domain of the protein (Pavletich et al., 1993) . These point mutants generally represent an inactive form of p53. They are unable to speci®cally bind to DNA and are impaired in their ability to transcriptionally activate p53-regulated promoters (Park et al., 1994) . As a consequence, cell cycle arrest, DNA repair and apoptosis are often dramatically decreased in tumour cells expressing these mutants. Transcriptional activity is an essential component of the p53-dependent induction of apoptosis. A p53 mutant bearing two point mutations within the transcriptional activation domain has kept its ability to speci®cally bind to DNA but has lost 90% of its transcriptional activity and its ability to induce apoptosis (Lin et al., 1994) . However, it should be noted that, in some speci®c cell lines, p53 mutants de®cient for transactivation function have retained their ability to induce apoptosis (Haupt et al., 1995) and that p53-induced apoptosis can also proceed without new protein synthesis (Caelles et al., 1994) . In addition, a proline-rich domain dispensable for transcriptional activation has recently been shown to mediate some of p53-associated apoptosis (Walker and Levine, 1996) .
The speci®c DNA binding capacity of p53 is negatively regulated by the carboxy-terminus of the protein. This inhibition can be relieved by partial proteolysis, DnaK association and by the action of some anti-p53 monoclonal antibodies (Hupp et al., 1992 (Hupp et al., , 1993 Halazonetis and Kandil, 1993; Hupp and Lane, 1994; Bayle et al., 1995; Waterman et al., 1995) . Thus, the monoclonal antibody (mAb) PAb421 (Harlow et al., 1981) is able to increase the sequencespeci®c DNA binding of wt p53 and to restore the sequence-speci®c DNA binding of some p53 mutants in vitro (Hupp et al., 1992 (Hupp et al., , 1995 Halazonetis and Kandil, 1993; Niewolik et al., 1995 , Abarzua et al., 1996 . Furthermore, microinjection experiments in tumour cells which express the endogeneous p53 mutant His273 have demonstrated that mAb PAb421 is also able to restore the transcriptional activity of this mutant in cells (Abarzua et al., 1995) . PAb421 is thought to induce a conformational change within the p53 molecule from an inactive structure to an active one. Similarly, p53 C-terminus derived peptides have been shown to induce apoptosis from some p53 mutants (Abarzua et al., 1996; Selivanova et al., 1997) .
Restoration of the speci®c DNA binding and transcriptional activity from p53 mutants could be sucient to trigger apoptosis and thus stop tumour progression. Based on the properties described above, the mAb PAb421 could constitute the basis for a therapeutic agent. Unfortunately, at present, an entire mAb cannot be easily introduced or expressed in tumour cells and one has to search for molecules mimicking the eect of PAb421 either as small molecular weight compounds or as cDNAs that could be expressed intracellularly for gene therapy applications. Single chain antibody fragments (scFvs) now represent a viable alternative as they constitute functional units that can be expressed intracellularly as single polypeptides. In addition, they are usually more stable than small peptides in cells, which are often degradated very quickly. In most cases, the scFv will exhibit properties similar to the parental antibody, with respect to selectivity and avidity. scFvs have been mostly derived from neutralizing monoclonal antibodies and have provided the basis for phenotypic knockouts via the binding and sometimes the relocalization of the targeted antigen (Richardson et al., 1995; Marasco, 1997) . We thus decided to generate two scFvs derived from the mouse PAb421 and 11D3 monoclonal antibodies. 11D3 belongs to a set of mAbs obtained from an immunization protocol (Biocytex, Marseille, France), using a mixture of four human p53 mutants (Val138, Trp248, His273, Gly281) expressed and puri®ed from baculovirus, as antigens. MAb 11D3 was selected for its ability to restore the DNA binding function of p53 mutants Trp248 and His273 in a gel retardation assay. ELISA showed that puri®ed IgG 11D3 bound less eciently than IgG Pab421 to immobilized p53 ( Figure 1a ). Both mAbs failed to bind a truncated recombinant p53 lacking the Cterminus domain (p53D320 ± 393) ( Figure 1c ). 11D3 epitope maps to the p53 carboxy-terminal end downstream from amino-acid 320, but is dierent from PAb421 epitope, as a decapeptide corresponding to the PAb421 epitope could not prevent 11D3 binding to p53 (data not shown).
Fragments corresponding to the V H and V L regions were ampli®ed by RT ± PCR using degenerated primers, from the corresponding hybridoma. Ā exible (Gly 4 -Ser) 3 linker was inserted between V H and V L regions (Orlandi et al., 1989) . The resulting scFv cDNAs were cloned into the pSW1 plasmid, allowing the secretion of scFvs containing the c-mycderived epitope at the C-terminus end into the periplasm of E. coli (Cochet et al., 1998) . A scFv11D3 clone was selected for further characterization. No functional candidates were initially obtained for the scFv421. Random sequencing revealed the presence of a single V H connected to various V L regions. N-terminal peptidic sequencing was performed on the heavy and light chains isolated from the parental antibody. Sequence comparisons revealed a match with the identi®ed V H region but no match to any of the cloned V L regions. Degenerated primers speci®c for the PAb421 V L region were then used and a scFv able to associate with p53 was obtained. This scFv was further characterized.
Sequence analysis of scFv421 and scFv11D3 using the Kabat database (Kabat et al., 1991) showed that both V H belong to subgroup IIC. Complementary Determining Region 2 (CDR 2) diered by 4 aminoacid residues. A major dierence was observed in CDR 3 with 11D3 V H showing 6 additional amino-acid residues (Figure 2 ). V k 11D3 belongs to subgroup I and V k 421 to subgroup II, with numerous amino-acid dierences in CDRs (Figure 2 ). Recently, a scFv (indicated as scFv421* in Figure 2 ) was derived from mAb PAb421 (Jannot and Hynes, 1997). Sequence Figure 1 ELISA in vitro binding of scFvs to immobilized full length but not C-terminus truncated p53 (p53D320 ± 393). Puri®ed mAbs PAb421 or 11D3 or periplasmic extracts containing scFvs 421 and 11D3 were incubated with either recombinant human wt p53 puri®ed from E. coli extract (a and b), or cytosolic extract from baculovirus-infected insect cells expressing p53D320 ± 393 (c). One hundred nanograms/well of full length p53, puri®ed from bacteria by anity-chromatography on mAb PAb421-coated-Protein A Sepharose (Amersham Pharmacia Biotech), or 300 ng/well of cytosolic fraction containing 20 ± 30% of p53D320 ± 393, from baculovirus-infected insect cells, were adsorbed onto a 96-well plate for 2 h at room temperature (RT). After washing, increasing amounts of puri®ed mAbs or scFv periplasmic extracts were incubated for 2 h at RT. scFvs were then detected with the anti-c-myc tag mouse mAb 9E10 (2 h at RT). Binding of 421, 11D3 and 9E10 mAbs was revealed by AP-labelled anti-mouse IgG goat antibodies (AP-GAM) (2 h at RT). MAbs PAb421 and 11D3 were puri®ed on Protein G Sepharose (Amersham Pharmacia Biotech). Periplasmic extracts were obtained as follows: overnight cultures of bacteria expressing scFvs were 100-fold diluted and incubated at 378C in presence of 0.1% glucose until 0.6 OD 600 1 mM IPTG was then added and the bacteria incubated at 288C for 4 h. (Figure 2 ). It should be noted that the scFv421* could never be detected in cell cytosol and nucleus and that no functional activities were reported, except an in vitro binding to immobilized GST-p53 Cterminus fusion molecule and to immobilized p53 in ELISA (Jannot and Hynes, 1997). ELISA indicated that scFvs 421 and 11D3 bind immobilized full length p53 but not p53D320 ± 393 (Figure 1b, c) . As already observed with the parental mAbs (Figure 1a) , scFv421 bound to p53 more eciently than scFv11D3 (Figure 1b) . In addition, both scFvs were also able to associate with soluble wt p53 in vitro, as shown by sandwich ELISA using the mAb DO1 (Dako) as capture antibody, a mAb which recognizes a N-terminus-located epitope (Figure 3) . Soluble p53D320 ± 393 was not bound by any of the scFvs in that assay (Figure 3) .
The scFvs were then tested for their ability to enhance the DNA binding activity of wt p53 or to restore the DNA binding activity of p53 mutant His273, by electrophoretic mobility shift assay. Both scFvs were able to enhance or restore the DNA binding of wt or mutant p53, respectively (Figure 4) . The super-shift associated with p53 was less pronounced when scFvs were used, as compared to the one observed with the corresponding parental mAbs. This is due to the lower apparent molecular mass of scFvs (28 kDa). This super-shift increased in a dosedependent manner, suggesting that, at higher concentrations, several scFv molecules are associated with p53 tetramers. Similar results were obtained using the Trp248 p53 mutant (data not shown). As these scFvs exhibited similar in vitro properties for p53 than the parental mAbs, we then studied their localization when expressed intracellularly ( Figure 5 ). The two scFvs were cloned in an eukaryotic expression vector. Two other constructs were also derived, in which the nuclear localization signal (NLS) from SV40 large T antigen was added at the C-terminus of the molecule. When the p53 7/7 H1299 human colon carcinoma cell line was transfected with the scFv421 cDNA alone, cytoplasmic staining and possibly nuclear staining were detectable (Figure 5a , upper left panel), showing that this scFv was stably expressed in the cells. The co-expression of the mutant p53 His273 greatly increased the concen- Figure 2 Comparison of deduced amino-acid sequences between 11D3, 421 and 421* V H and V k scFvs. Amino-acid numbering is according to Kabat et al. (1991) . 421* amino-acid sequence data are from Jannot and Hynes (1997) . Positions at which at least two of the three sequences possess the same residue are shown by shaded areas. Sequences have been deposited in the EMBL nucleotide sequence database under the accession numbers AJ131532 and AJ131533 Figure 3 scFvs stably bind to soluble p53 in vitro. MAb DO1 (IgG2a, k) was coated onto ELISA plates (2 mg/ml, 2 h at RT). Full length p53 (dotted lines) or p53D320 ± 393 (solid lines) (obtained as in Figure 1 ) were then added (125 ng/ml) and incubated overnight at 48C. After washing, scFvs 421 or 11D3-containing periplasmic extracts were twofold diluted (starting dilution: 1/2) in PBS-1% BSA and incubated for 2 h at RT. scFvs were revealed with mAb 9E10 (2 mg/ml) (IgG1, k) and APlabelled goat anti-mouse IgG1 antibodies. scFv421, open circle; scFv11D3, open square Targeting scFvs to mutant p53 to restore transactivation C Caron de Fromentel et al tration of the scFv421 in the nucleus (Figure 5a , lower left panel), suggesting that p53 and the scFv were able to associate in cells and that p53 was able to drive the scFv into the nucleus. When H1299 cells were transfected with the scFv421-NLS cDNA, a larger fraction of the scFv was localized in the nucleus (Figure 5b, upper left panel) . The coexpression of p53 His273 reinforced this localization (Figure 5b , lower left panel). The detection of the scFv11D3 was unsuccessful, likely due to a much lower intracellular level expression. However, the scFv11D3 expressed in H1299 cells could be detected in a whole cell extract by Western blotting, although very weakly with regard to scFv421 (data not shown). Amino-acid residues are likely to be critical for proper expression, folding and stability of scFvs (Nieba et al., 1997) . Thus, the changes in V H and V L sequences between scFv421 and scFv11D3 may account for the dierences of expression and of binding observed.
Based on these observations, we then tested the ability of the scFvs to restore the DNA binding activity and the transcriptional function of p53 mutants. The p53 7/7 tumour cell line H1299 was cotransfected with various combinations of plasmids encoding the chloramphenicol acetyl transferase (CAT) reporter gene under the control of a p53 responsive element a b Figure 4 The scFvs enhance the DNA binding ability of p53 in vitro. Periplasmic extract of scFv421 (a) or scFv11D3 (b) was incubated with puri®ed wild-type or mutant p53 His273, and DNA binding determined by electrophoretic mobility shift assay. Thirty ng of wild-type p53 or mutant His273 from baculovirus-infected cells, puri®ed on mAb PAb421 bound to Protein A Sepharose (Amersham Pharmacia Biotech), were incubated for 30 min at 48C with increasing amounts of periplasmic extract of scFv in 25 ml of binding buer (20 mM Tris, pH 7.5, 100 mM NaCl, 10% glycerol, 1% NP-40, 5 mM DTT, 50 mM ZnCl 2 , 5 mM MgCl 2 , 0.01% BSA, 0.3 mM aprotinin, 1 mM leupeptin, 1.4 mM E64). Then, 0.06 pmoles of WAF1 oligonucleotide and 24 pmoles of AP2 oligonucleotide were added and incubation continued for 30 min at 48C. Reaction mixtures were loaded onto a native 4% polyacrylamide gel (30 : 0.8 w/w acrylamide:bisacrylamide) and the gel run at 150 volts for 90 min at 48C in 0.336TBE, 0.1% Triton X100. Three hundred nanograms of mAb PAb421, 11D3 or HR231 (Legros et al., 1994) were used in place of scFv, as control. Oligonucleotide probe was prepared as follows: 5 pmoles of oligonucleotide WAF1 upper (5'-GATCCGAACATGTCC-CAACATGTTGA-3'), or WAF1 lower (5'-AGCTTCAACATGTTGGGACATGTTCG-3') were incubated with 6.5 ml of 33 P-g-ATP (3000 Ci/mmole) and 10 units of T4 polynucleotide kinase (Boehringer) in buer purchased from the manufacturer, for 30 min at 378C. The labelled oligonucleotides were then mixed and hybridized, in presence of 100 mM NaCl, by heating 3 min at 958C and slowly decreasing until room temperature. Two nmoles of unlabelled oligonucleotides AP2 upper (5'-GATCGAACT-GACCGCCCGCGGCCCGT-3') and AP2 lower (5'-ACGGGCCGCGGGCGGTCAGTTCGATC-3') were mixed in 10 mM Tris, pH 7.4, 100 mM NaCl and hybridized as described above. The two hybridized oligonucleotides were then mixed and puri®ed on a Nick Spin column (Amersham Pharmacia Biotech), according to the manufacturer's instructions (RE), the scFvs, wt p53, or p53 mutant His273 or His175. The expression of the scFvs, scFvs-NLS or the p53 mutant His175 did not aect the basal level of CAT activity (Figure 6 ). The expression of the p53 mutant His273 led to a weak transcriptional activity, corresponding to 10% of the signal obtained with wt p53. Coexpression of either scFvs or scFv421-NLS with the p53 mutant His273 led to an increase in the His273-associated transcriptional activity. This eect was not observed with the His175 mutant which had previously been shown to be unsensitive to Pab421 activation (Hupp et al., 1993) . This also demonstrated that the in vivo restoration of p53 transactivation function by these scFvs was not due to a non p53-mediated eect. Surprisingly with regard to its lower apparent binding ability and cellular expression, the scFv11D3 was as ecient as the scFv421 in this assay. It is possible that the scFv11D3 which recognizes a dierent epitope induces a conformational change more favourable for transcriptional activation in vivo than the scFv421. The two scFv421 constructs were also ecient in enhancing the transcriptional activity of Figure 5 Cellular localization of scFv421. scFv421 (a) and scFv421-NLS (b) were expressed in a p53
7/7 tumour cell line, in presence or in absence of p53 mutant His273, and localization was determined by immuno¯uorescence. p53 7/7 human lung carcinoma cell line H1299 was grown in 2-well-LabTek chamber slides (NUNC) (5610 4 cells/well) for 24 h and transfected with 250 ng of plasmid encoding scFv421 or scFv421-NLS cDNA, with or without 250 ng of plasmid encoding p53 mutant His273 cDNA. Transfection was performed using lipofectamine (Life Technologies) according to the manufacturer's instructions, except the following modi®cation: a small peptide (Byk et al., 1995) was added to DNA (3.2 mg of peptide per mg of DNA) before addition of lipofectamine. Brie¯y, 500 ng of DNA were mixed with peptide in Opti-MEM (Life Technologies) and incubated for 10 min at room temperature. Then, 2 ml of lipofectamine in Opti-MEM were added and incubation continued for 30 min at room temperature. Cells were maintained in this medium for 4 h, at 378C. Twenty-four hours later, immuno¯uorescence assay was done. After two washes in PBS, permeabilization was performed by incubation for 10 min at room temperature in acetone-methanol (vol/ vol). After two washes in PBS and saturation with PBS-1% BSA (10 min, room temperature), slides were incubated for 30 min at room temperature, with the mouse anti-p53 mAb DO1 (DAKO) (10 mg/ml) and a rabbit anti-scFv polyclonal serum (1/300) (Cochet et al., 1998) diluted in PBS-1% BSA. Cells were then washed and incubated with a goat anti-mouse IgG serum coupled to Texas Red (Jackson Immunoresearch) (1/300) and a goat anti-rabbit IgG serum coupled to FITC (Jackson Immunoresearch) (1/200). The slides were counterstained with Vectashield with DAPI (Vector) and observed under a¯uorescence microscope Targeting scFvs to mutant p53 to restore transactivation C Caron de Fromentel et al p53 mutant His273 endogenously expressed in three dierent human tumour cell lines (A431: epidermoid carcinoma; HT29, SW480: adenocarcinomas of the colon), or of p53 mutant Leu248 found in the H322 non small cell lung carcinoma cell line (data not shown). Thus, both scFv421 and scFv11D3 could restore p53 transactivation function in vivo.
In summary, the results reported here demonstrate that scFvs can be used for restoring a function essential for the tumour suppressor activity of p53 to some p53 mutants in cells. They could constitute new molecules for p53-based cancer therapy. Furthermore, this work is the ®rst example where intracellular scFvs are not only used as neutralizing molecules, but supply a gain of function, i.e. the restoration of the de®cient transactivating function of a nuclear transcription factor. Figure 6 The scFvs restore transcriptional activity to p53 mutant. Transcriptional activity of exogenous p53 mutant His273 was measured in absence or in presence of scFvs in a CAT assay. The p53 7/7 human lung carcinoma cell line H1299 was grown in a 6-well-plate (3.5610 5 cells/well) for 24 h and transfected by lipofectamine procedure (5 ml of lipofectamine were used in this case), with plasmid expressing the CAT reporter gene under the control of the p53 speci®c responsive element (RE) (Funk et al., 1992) (500 ng) and various combinations of plasmids encoding p53 mutants (His273 or His175), or scFvs (421, 421-NLS or 11D3) (500 ng each). Forty-eight hours later, proteins were extracted by three successive freezings in 100 ml of 250 mM Tris, pH 8.0. An enzymatic assay was performed with 80 ml of protein extract, 16 ml of Acetyl Coenzyme A, 4 ml of 14 C Chloramphenicol (NEN) and 50 ml of 250 mM Tris, pH 8.0, for 1 h at 378C. After chromatography, acetylation was quantitated using an Instant Imager (Packard Instruments). Data are expressed as the mean of four independent experiments
